BioNTech advocate accused of undermining WHO’s African mRNA production campaign: reportnews2022-02-09T19:08:14+00:00February 9th, 2022|Fierce Pharma|
GlaxoSmithKline’s COVID-19 antibody delivers as Nucala, Trelegy eclipse £1B landmarknews2022-02-09T16:25:36+00:00February 9th, 2022|Fierce Pharma|
Teva banks on blockbuster Austedo sales as COVID-19, Copaxone generics take their tollnews2022-02-09T14:55:40+00:00February 9th, 2022|Fierce Pharma|
Roche pharma CEO Anderson talks up Vabysmo’s ‘very strong launch’ plans as Eylea battle loomsnews2022-02-09T14:54:13+00:00February 9th, 2022|Fierce Pharma|
Karyopharm ready to take new Xpovio indication to the FDA but analysts hold out for detailsnews2022-02-09T13:46:35+00:00February 9th, 2022|Fierce Pharma|
Amgen talks long-term growth, but doubts remain for analysts, investorsnews2022-02-08T19:41:30+00:00February 8th, 2022|Fierce Pharma|
J&J pauses COVID-19 vaccine production at Dutch plant in temporary pivot to RSV shot: NYTnews2022-02-08T18:51:59+00:00February 8th, 2022|Fierce Pharma|
Eli Lilly, Innovent’s PD-1 in troubled waters as FDA review, oncology chief’s comments portend likely rejectionnews2022-02-08T18:06:30+00:00February 8th, 2022|Fierce Pharma|
As Pfizer reaps megablockbuster COVID-19 sales, CEO doesn’t see virus going away for ‘foreseeable future’news2022-02-08T16:28:12+00:00February 8th, 2022|Fierce Pharma|
Incyte’s eczema cream Opzelura off to ‘very successful’ launch despite FDA warning: CEOnews2022-02-08T15:52:44+00:00February 8th, 2022|Fierce Pharma|
